Document Detail

Monotherapy with metformin: does it improve hypoxia in type 2 diabetic patients?
MedLine Citation:
PMID:  11601679     Owner:  NLM     Status:  MEDLINE    
Metformin reduces blood glucose levels predominantly by inhibiting hepatic gluconeogenesis, although it also may enhance insulin receptor number or activity. The full effects of metformin are still poorly understood. In this study the effects of metformin on plasma xanthine oxidase (XO) activity, thiobarbituric acid-reactive substance (TBARS), lactate and fructosamine concentration as well as erythrocyte antioxidant enzyme activities were investigated in 46 patients with type 2 diabetes mellitus. All parameters were measured simultaneously just before metformin therapy (T0), 1 month (T1) and 2 months (T2) later. Results were compared with placebo and control group. We noted significant decrease in XO activity and in TBARS concentration (p<0.001) during monotherapy with metformin vs. placebo and T0 group. A significant correlation was observed between the activity of XO and the concentration of fructosamine (p<0.001). Erythrocyte glutathione peroxidase showed significantly lower activity in T2 group in comparison with T0 group (p<0.01). It is known that diabetic patients produce more TBARS as a result of enhanced free radical generation the source of which may also be the large amounts of XO produced following the conversion of xanthine dehydrogenase in hypoxic diabetic tissues. Thus, our results indirectly suggest that metformin can reduce toxic tissue damage through the inhibition on XO activity.
V Cosić; S Antić; M Pesić; O Jovanović; S Kundalić; V B Djordjević
Related Documents :
21105109 - Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related met...
16969429 - Vildagliptin: a novel dpp-4 inhibitor with pancreatic islet enhancement activity for tr...
8435549 - Treating non-insulin-dependent diabetes. oral agents or insulin?
6439409 - Glyburide (diabeta): a new second-generation hypoglycemic agent.
17428109 - Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct...
16199429 - Combined lifestyle modification and metformin in obese patients with polycystic ovary s...
3147659 - A study of the response to several dipsogenic treatments in rats with mammillary polydi...
15819959 - Acute insulin-induced hypoglycaemia does not alter igf-1 and lh release in cyclic mares.
19781509 - Cardiovascular disease in persons with spinal cord dysfunction-an update on select topics.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical chemistry and laboratory medicine : CCLM / FESCC     Volume:  39     ISSN:  1434-6621     ISO Abbreviation:  Clin. Chem. Lab. Med.     Publication Date:  2001 Sep 
Date Detail:
Created Date:  2001-10-16     Completed Date:  2002-03-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9806306     Medline TA:  Clin Chem Lab Med     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  818-21     Citation Subset:  IM    
Centre of Medical Biochemistry, Clinical Centre Nis, Yugoslavia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anoxia / drug therapy*,  metabolism,  physiopathology
Antioxidants / metabolism
Catalase / metabolism
Diabetes Mellitus, Type 2 / drug therapy*,  metabolism,  physiopathology
Hypoglycemic Agents / therapeutic use*
Metformin / therapeutic use*
Middle Aged
Superoxide Dismutase / metabolism
Thiobarbituric Acid Reactive Substances / metabolism
Xanthine Oxidase / metabolism
Reg. No./Substance:
0/Antioxidants; 0/Hypoglycemic Agents; 0/Thiobarbituric Acid Reactive Substances; 657-24-9/Metformin; EC; EC Dismutase; EC Oxidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Detection and quantification of small numbers of circulating tumour cells in peripheral blood using ...
Next Document:  Cigarette smoking and hypertension influence nitric oxide release and plasma levels of adhesion mole...